An Efficacy and Safety Study of LTG-001 Following Abdominoplasty
Trial details
- Registry ID
- NCT07102459
- Drugs studied
- Active Comparator: HB/APAP, Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose
TrialRedline tracks 2 clinical trials sponsored by Latigo Biotherapeutics: 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Efficacy and Safety Study of LTG-001 Following AbdominoplastyNCT07102459 | Active Comparator: HB/APAP, Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose | Completed | 2026-01-07Actual |
| This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third MolarsNCT06774625 | LTG-001 High Dose, LTG-001 Low Dose, LTG-001 Mid Dose, Suzetrigine | Completed | 2025-08-08Actual |
Names as written in the registry records.
NCT07102459 · Latigo Biotherapeutics
Before: Estimated. After: Actual.
Before: 360 participants (planned). After: 343 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2025. After: 7 Jan 2026.
Before: Recruiting. After: Completed.